View ValuationElekta 향후 성장Future 기준 점검 3/6Elekta (는) 각각 연간 34.8% 및 4.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 35.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.3% 로 예상됩니다.핵심 정보34.8%이익 성장률35.47%EPS 성장률Medical Equipment 이익 성장13.5%매출 성장률4.6%향후 자기자본이익률18.34%애널리스트 커버리지Good마지막 업데이트26 May 2026최근 향후 성장 업데이트공시 • Aug 28Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter. The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year.공시 • May 25+ 1 more updateElekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025Elekta AB (publ) provided earnings guidance for the fiscal year from 2022-2023 to 2024-2025. For the period, the company expects net sales CAGR of above 7%.모든 업데이트 보기Recent updates공시 • May 19Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026공시 • Mar 05+ 1 more updateElekta AB (publ) to Report Q2, 2027 Results on Nov 25, 2026Elekta AB (publ) announced that they will report Q2, 2027 results on Nov 25, 2026공시 • Feb 26Elekta AB (publ), Annual General Meeting, Sep 03, 2026Elekta AB (publ), Annual General Meeting, Sep 03, 2026.공시 • Jan 23Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026Elekta AB has established the role of Vice Chair of the Board and appointed Tomas Eliasson to this position, effective January 23, 2026. Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation.공시 • Jan 16Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear AcceleratorElekta announced that its Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris®? high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities.공시 • Sep 04+ 1 more updateElekta AB (Publ) Elects Jan De Witte as DirectorElekta AB (publ) at its AGM held on September 4, 2025 approved to elect Jan De Witte, as Director for the period until the end of the next Annual General Meeting.공시 • Aug 28Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter. The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year.공시 • May 29Elekta AB (publ), Annual General Meeting, Sep 04, 2025Elekta AB (publ), Annual General Meeting, Sep 04, 2025.공시 • May 28+ 1 more updateElekta AB (publ) Proposes Dividend for the Fiscal Year 2024/25The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.40) per share (paid in two installments) for 2024/25 amounting to SEK 917 million.공시 • May 19+ 1 more updateElekta AB (publ) to Report Q3, 2026 Results on Mar 05, 2026Elekta AB (publ) announced that they will report Q3, 2026 results on Mar 05, 2026공시 • May 05Elekta Announces Use of Its 1.5T Elekta Unity MR-LinacElekta announced that use of its 1.5T Elekta Unity MR-Linac can enable doctors to reduce the radiation dose to key structures responsible for erection among men being treated for prostate cancer. The preliminary results of the ERECT (EREctile Function Preservation for Prostate Cancer Radiation Therapy) trial were presented by University Medical Center Utrecht (UMC Utrecht, the Netherlands) clinicians at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual congress, May 2-6 in Vienna, Austria. The ERECT Trial is a sub-study of MOMENTUM, the MR-Linac Consortium's platform registry. It showed reduced incidence of erectile dysfunction (ED) and preserved erectile function up to 18 months using MR-guided radiotherapy (MRgRT) compared to conventional radiotherapy in patients with localized prostate cancer. In the study, researchers used Elekta Unity MR- Linac to treat 70 intermediate risk prostate cancer patients with a radiation dose of 36.25 Gy over five fractions. According to UMC Utrecht radiation oncologist and trial principal investor, Jochem van der Voort van Zyp, MD, PhD, Unity's pristine MR image quality not only enabled detailed visualization of the prostate, but also that of critical structures needed to achieve and maintain an erection. This anatomy includes the neurovascular bundle, internal pudendal arteries, corpora cavernosa and penile bulb. The endpoint of this preliminary analysis was the incidence of ED - as reported by patients - at six, 12- and 18-months post-treatment, compared to a control group that received the same dosage without neurovascular sparing. ED incidence was significantly lower in ERECT patients at all time points (six months: 6% vs. 21%, 12 months: 8.5% vs. 38%, 18 months: 16% vs. 36%). MRI is the gold standard for visualizing the prostate and surrounding structures in diagnostic radiology. Elekta Unity MR-Liac is the world's first and only device to combine a high-field MRI with a linear accelerator and enables clinicians to use MRI to guide radiation delivery to tumor targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If for example, if a prostate shifts due to motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues.공시 • Feb 27+ 1 more updateElekta AB (Publ) Announces Management ChangesElekta AB (publ) announced that Gustaf Salford, President and the Board of Directors, have decided that Gustaf will leave Elekta as of March 6, 2025. The Board of Directors has appointed Jonas Bolander, who has 23 years' experience at Elekta, as Acting President.공시 • Nov 27+ 2 more updatesElekta AB (publ) to Report Q2, 2026 Results on Nov 26, 2025Elekta AB (publ) announced that they will report Q2, 2026 results on Nov 26, 2025공시 • Nov 01Caroline Leksell Cooke Steps Down from Elekta AB's Board of DirectorsElekta AB announced that Caroline Leksell Cooke will step down from her role on the Board of Directors, effective November 1, 2024. This follows the earlier announcement that Caroline Leksell Cooke will assume the role of Senior Vice President and Head of Neuro Solutions, effective the same date, and in connection therewith leave her position as a board member.공시 • Sep 27Elekta AB Submits Elekta Evo to U.S. FDA for Premarket ApprovalElekta AB announced that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo has been submitted and is now pending 510(k) premarket approval from the U.S. Food and Drug Administration (FDA) - this, less than a week after Evo received CE mark for sales and marketing in the European Union.공시 • Sep 06Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, RespectivelyElekta AB (publ) at its AGM held on September 5, 2024, approved dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is September 9, 2024. The second record day is March 7, 2025. The dividend is expected to be paid out on September 12, 2024, and on March 12, 2025, respectively.공시 • Jul 06Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025Elekta AB (publ) announced that they will report Q4, 2025 results on May 28, 2025공시 • Jun 06Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025Elekta AB (publ) announced that they will report Q3, 2025 results on Feb 21, 2025공시 • Mar 02Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the BoardElekta AB announced that Kelly Londy, Member of the Board, will step down from her position and all board responsibilities, effective March 1, 2024. Ms. Londy has assumed a new senior executive role at another company, which will require her full attention. She has contributed significantly to Elekta’s Board and been greatly appreciated by her fellow board members. Elekta expresses its sincere gratitude to Ms. Londy for her dedicated service and wishes her continued success in her future role.공시 • Feb 29Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024Elekta AB (publ) announced that they will report Q2, 2025 results on Nov 27, 2024공시 • Nov 30+ 1 more updateElekta AB (publ) to Report Fiscal Year 2024 Final Results on Jul 05, 2024Elekta AB (publ) announced that they will report fiscal year 2024 final results on Jul 05, 2024공시 • Nov 01Elekta AB (publ) Announces Composition of Nomination CommitteeElekta AB (publ) announced that Annual General Meeting on August 24, 2023, the Chairman of the Board has convened the Nomination Committee for the 2024 Annual General Meeting by contacting the company's shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself. The procedure is described in detail in the notice to the 2020 Annual General Meeting. The Nomination Committee consists of: Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties' holdings; Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund; Katarina Hammar, appointed by Nordea Funds; Patrik Jönsson, appointed by SEB Funds; Jesper Bergström, appointed by Handelsbanken Funds.공시 • Oct 24Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD) on October 23, 2023. The intention is to complete the transaction during the second quarter of Elekta’s fiscal year 2023/24.공시 • Oct 13Elekta AB (publ), Annual General Meeting, Sep 05, 2024Elekta AB (publ), Annual General Meeting, Sep 05, 2024.공시 • Aug 25+ 1 more updateElekta AB (Publ) Approves Dividend, Payable on 31 August, 2023 and 1 March, 2024, RespectivelyElekta AB (publ) announced that at its AGM held on 24 August 2023, the Meeting resolved on a dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is 28 August, 2023. The second record day is 27 February, 2024. The dividend is expected to be paid out on 31 August, 2023 and on 1 March, 2024 respectively.공시 • Jun 30Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ)Elekta AB (publ) announced that 2023 Annual General Meeting to held on 24 August 2023, Johan Malmquist has declined re-election as director of the company.공시 • May 26+ 1 more updateElekta AB (publ) to Report Q3, 2024 Results on Feb 29, 2024Elekta AB (publ) announced that they will report Q3, 2024 results on Feb 29, 2024공시 • May 25+ 1 more updateElekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025Elekta AB (publ) provided earnings guidance for the fiscal year from 2022-2023 to 2024-2025. For the period, the company expects net sales CAGR of above 7%.공시 • May 13Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONEElekta AB (publ) is excited to announced the launch of the first phase of Elekta ONE, its most comprehensive and advanced software portfolio for oncology departments and clinics, including radiation therapy planning, comprehensive treatment management, and delivery. It brings all Elekta software products, solutions and services under one umbrella providing all users with one unified software experience. Previously, many cancer clinics have wrestled with stand-alone, closed systems, each with a different purpose. The result has been an unfavorable user experience and steep learning curve, adding pressure to an already strained resource: the clinical team. Elekta ONE aims to improve efficiency in the clinic by as much as 50%, eventually through smarter workflows, increased automation, and by learning from every patient treated. Its workflow-driven approach and deep integration between applications allows information to flow freely, giving clinicians a seamless user experience.공시 • Feb 14Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter.Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter on February 13, 2023. The first quarter of Elekta’s fiscal year 2023-2024.공시 • Nov 24Elekta AB (publ), Annual General Meeting, Aug 24, 2023Elekta AB (publ), Annual General Meeting, Aug 24, 2023.공시 • Jul 09+ 1 more updateElekta AB (publ) to Report Fiscal Year 2023 Results on May 25, 2023Elekta AB (publ) announced that they will report fiscal year 2023 results on May 25, 2023이익 및 매출 성장 예측MUN:EJX - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수4/30/202919,7081,7341,4952,17454/30/202818,5281,6111,6392,949134/30/202717,6791,4401,5132,776144/30/202616,9678508961,941141/31/202617,111-401,4992,652N/A10/31/202517,5672921,9753,214N/A7/31/202517,8372741,5853,033N/A4/30/202518,0162371,0562,626N/A1/31/202517,8821,0386822,375N/A10/31/202417,7241,0025832,352N/A7/31/202418,1161,1348242,519N/A4/30/202418,1191,3028172,461N/A1/31/202418,2211,4331,5163,135N/A10/31/202318,0211,3447232,289N/A7/31/202317,3701,121961,611N/A4/30/202316,8699434001,964N/A1/31/202315,984813-5511,013N/A10/31/202215,249826-2011,361N/A7/31/202214,8661,0872001,741N/A4/30/202214,5481,1544501,858N/A1/31/202213,9761,0796481,933N/A10/31/202113,9551,1729582,049N/A7/31/202113,7911,1651,3022,259N/A4/30/202113,7631,2541,7062,551N/A1/31/202114,1041,3211,7392,680N/A10/31/202014,1791,3071,0881,970N/A7/31/202014,3541,1531,0441,854N/A4/30/202014,6011,0842521,014N/A1/31/202014,6801,2126231,318N/A10/31/201914,3431,115N/A1,281N/A7/31/201913,9641,179N/A1,373N/A4/30/201913,5551,198N/A1,621N/A1/31/201912,8771,164N/A1,307N/A10/31/201812,3151,295N/A2,056N/A7/31/201811,8881,315N/A1,947N/A4/30/201811,5731,348N/A2,404N/A1/31/201811,879939N/A2,393N/A10/31/201711,795639N/A2,095N/A7/31/201711,326389N/A2,034N/A4/30/201710,704125N/A1,819N/A1/31/201710,596108N/A1,442N/A10/31/201610,47070N/A1,375N/A7/31/201610,864203N/A1,380N/A4/30/201611,221137N/A1,170N/A1/31/201611,469402N/A1,989N/A10/31/201511,474548N/A1,862N/A7/31/201511,213558N/A1,952N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: EJX 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(1.9%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: EJX (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: EJX 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: EJX 의 수익(연간 4.6%)이 German 시장(연간 6.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: EJX 의 수익(연간 4.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: EJX의 자본 수익률은 3년 후 18.3%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/27 03:31종가2026/05/27 00:00수익2026/01/31연간 수익2025/04/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Elekta AB (publ)는 30명의 분석가가 다루고 있습니다. 이 중 14명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관null nullABG Sundal CollierSally TaylorBarclaysHassan Al-WakeelBarclays27명의 분석가 더 보기
공시 • Aug 28Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter. The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year.
공시 • May 25+ 1 more updateElekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025Elekta AB (publ) provided earnings guidance for the fiscal year from 2022-2023 to 2024-2025. For the period, the company expects net sales CAGR of above 7%.
공시 • May 19Elekta AB (publ) to Report Fiscal Year 2026 Final Results on Jul 03, 2026Elekta AB (publ) announced that they will report fiscal year 2026 final results at 9:00 AM, Central European Standard Time on Jul 03, 2026
공시 • Mar 05+ 1 more updateElekta AB (publ) to Report Q2, 2027 Results on Nov 25, 2026Elekta AB (publ) announced that they will report Q2, 2027 results on Nov 25, 2026
공시 • Feb 26Elekta AB (publ), Annual General Meeting, Sep 03, 2026Elekta AB (publ), Annual General Meeting, Sep 03, 2026.
공시 • Jan 23Elekta AB Appoints Tomas Eliasson as Vice Chair of the Board, Effective January 23, 2026Elekta AB has established the role of Vice Chair of the Board and appointed Tomas Eliasson to this position, effective January 23, 2026. Tomas Eliasson has been a member of Elekta’s Board of Directors since 2023 and the Chair of its Audit Committee since 2024. He brings extensive experience from senior leadership and board roles in global industrial and technology-driven companies. His background includes deep expertise in finance, governance and strategy, supporting Elekta’s continued focus on long-term value creation.
공시 • Jan 16Elekta Receives FDA 510(K) Clearance for Elekta Evo Linear AcceleratorElekta announced that its Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs-at-risk. Evo addresses this with Iris®? high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction, setting new benchmarks in radiation therapy as more clinics adopt its innovative treatment capabilities.
공시 • Sep 04+ 1 more updateElekta AB (Publ) Elects Jan De Witte as DirectorElekta AB (publ) at its AGM held on September 4, 2025 approved to elect Jan De Witte, as Director for the period until the end of the next Annual General Meeting.
공시 • Aug 28Elekta AB (publ) Provides Earnings Guidance for the Second Quarter 2025-2026 and Reiterates Earnings Guidance for the Year 2025-2026Elekta AB (publ) provided earnings guidance for the second quarter 2025-2026 and reiterated earnings guidance for the year 2025-2026. The company expects net sales for second quarter to be negatively impacted by a continued weak US development as well as a negative effect from last year's low order intake in China. However, The company expects sales in China to start to recover during the second half of 2025/26. Furthermore, company expect a continuous negative impact on earnings from FX at current exchange rates and from tariffs in second quarter. The company reiterates full year 2025-2026 outlook, where the company expects net sales in constant currency to grow year-over-year.
공시 • May 29Elekta AB (publ), Annual General Meeting, Sep 04, 2025Elekta AB (publ), Annual General Meeting, Sep 04, 2025.
공시 • May 28+ 1 more updateElekta AB (publ) Proposes Dividend for the Fiscal Year 2024/25The Board of Directors of Elekta AB (publ) proposed a dividend of SEK 2.40 (SEK 2.40) per share (paid in two installments) for 2024/25 amounting to SEK 917 million.
공시 • May 19+ 1 more updateElekta AB (publ) to Report Q3, 2026 Results on Mar 05, 2026Elekta AB (publ) announced that they will report Q3, 2026 results on Mar 05, 2026
공시 • May 05Elekta Announces Use of Its 1.5T Elekta Unity MR-LinacElekta announced that use of its 1.5T Elekta Unity MR-Linac can enable doctors to reduce the radiation dose to key structures responsible for erection among men being treated for prostate cancer. The preliminary results of the ERECT (EREctile Function Preservation for Prostate Cancer Radiation Therapy) trial were presented by University Medical Center Utrecht (UMC Utrecht, the Netherlands) clinicians at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual congress, May 2-6 in Vienna, Austria. The ERECT Trial is a sub-study of MOMENTUM, the MR-Linac Consortium's platform registry. It showed reduced incidence of erectile dysfunction (ED) and preserved erectile function up to 18 months using MR-guided radiotherapy (MRgRT) compared to conventional radiotherapy in patients with localized prostate cancer. In the study, researchers used Elekta Unity MR- Linac to treat 70 intermediate risk prostate cancer patients with a radiation dose of 36.25 Gy over five fractions. According to UMC Utrecht radiation oncologist and trial principal investor, Jochem van der Voort van Zyp, MD, PhD, Unity's pristine MR image quality not only enabled detailed visualization of the prostate, but also that of critical structures needed to achieve and maintain an erection. This anatomy includes the neurovascular bundle, internal pudendal arteries, corpora cavernosa and penile bulb. The endpoint of this preliminary analysis was the incidence of ED - as reported by patients - at six, 12- and 18-months post-treatment, compared to a control group that received the same dosage without neurovascular sparing. ED incidence was significantly lower in ERECT patients at all time points (six months: 6% vs. 21%, 12 months: 8.5% vs. 38%, 18 months: 16% vs. 36%). MRI is the gold standard for visualizing the prostate and surrounding structures in diagnostic radiology. Elekta Unity MR-Liac is the world's first and only device to combine a high-field MRI with a linear accelerator and enables clinicians to use MRI to guide radiation delivery to tumor targets and avoid surrounding structures. In addition, while treatment is ongoing, the system allows clinicians to non-invasively monitor the position of the target. If for example, if a prostate shifts due to motion of the bowels or bladder filling, the radiation treatment can be discontinued to avoid unnecessary radiation to surrounding normal tissues.
공시 • Feb 27+ 1 more updateElekta AB (Publ) Announces Management ChangesElekta AB (publ) announced that Gustaf Salford, President and the Board of Directors, have decided that Gustaf will leave Elekta as of March 6, 2025. The Board of Directors has appointed Jonas Bolander, who has 23 years' experience at Elekta, as Acting President.
공시 • Nov 27+ 2 more updatesElekta AB (publ) to Report Q2, 2026 Results on Nov 26, 2025Elekta AB (publ) announced that they will report Q2, 2026 results on Nov 26, 2025
공시 • Nov 01Caroline Leksell Cooke Steps Down from Elekta AB's Board of DirectorsElekta AB announced that Caroline Leksell Cooke will step down from her role on the Board of Directors, effective November 1, 2024. This follows the earlier announcement that Caroline Leksell Cooke will assume the role of Senior Vice President and Head of Neuro Solutions, effective the same date, and in connection therewith leave her position as a board member.
공시 • Sep 27Elekta AB Submits Elekta Evo to U.S. FDA for Premarket ApprovalElekta AB announced that its AI-powered adaptive CT-Linear Accelerator, Elekta Evo has been submitted and is now pending 510(k) premarket approval from the U.S. Food and Drug Administration (FDA) - this, less than a week after Evo received CE mark for sales and marketing in the European Union.
공시 • Sep 06Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, RespectivelyElekta AB (publ) at its AGM held on September 5, 2024, approved dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is September 9, 2024. The second record day is March 7, 2025. The dividend is expected to be paid out on September 12, 2024, and on March 12, 2025, respectively.
공시 • Jul 06Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025Elekta AB (publ) announced that they will report Q4, 2025 results on May 28, 2025
공시 • Jun 06Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025Elekta AB (publ) announced that they will report Q3, 2025 results on Feb 21, 2025
공시 • Mar 02Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the BoardElekta AB announced that Kelly Londy, Member of the Board, will step down from her position and all board responsibilities, effective March 1, 2024. Ms. Londy has assumed a new senior executive role at another company, which will require her full attention. She has contributed significantly to Elekta’s Board and been greatly appreciated by her fellow board members. Elekta expresses its sincere gratitude to Ms. Londy for her dedicated service and wishes her continued success in her future role.
공시 • Feb 29Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024Elekta AB (publ) announced that they will report Q2, 2025 results on Nov 27, 2024
공시 • Nov 30+ 1 more updateElekta AB (publ) to Report Fiscal Year 2024 Final Results on Jul 05, 2024Elekta AB (publ) announced that they will report fiscal year 2024 final results on Jul 05, 2024
공시 • Nov 01Elekta AB (publ) Announces Composition of Nomination CommitteeElekta AB (publ) announced that Annual General Meeting on August 24, 2023, the Chairman of the Board has convened the Nomination Committee for the 2024 Annual General Meeting by contacting the company's shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself. The procedure is described in detail in the notice to the 2020 Annual General Meeting. The Nomination Committee consists of: Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties' holdings; Thomas Wuolikainen, appointed by the Fourth Swedish National Pension Fund; Katarina Hammar, appointed by Nordea Funds; Patrik Jönsson, appointed by SEB Funds; Jesper Bergström, appointed by Handelsbanken Funds.
공시 • Oct 24Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD) on October 23, 2023. The intention is to complete the transaction during the second quarter of Elekta’s fiscal year 2023/24.
공시 • Oct 13Elekta AB (publ), Annual General Meeting, Sep 05, 2024Elekta AB (publ), Annual General Meeting, Sep 05, 2024.
공시 • Aug 25+ 1 more updateElekta AB (Publ) Approves Dividend, Payable on 31 August, 2023 and 1 March, 2024, RespectivelyElekta AB (publ) announced that at its AGM held on 24 August 2023, the Meeting resolved on a dividend corresponding to SEK 2.40 per share and that the remaining profits are carried forward. The dividend is to be divided into two payments of SEK 1.20 per payment. The first record day is 28 August, 2023. The second record day is 27 February, 2024. The dividend is expected to be paid out on 31 August, 2023 and on 1 March, 2024 respectively.
공시 • Jun 30Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ)Elekta AB (publ) announced that 2023 Annual General Meeting to held on 24 August 2023, Johan Malmquist has declined re-election as director of the company.
공시 • May 26+ 1 more updateElekta AB (publ) to Report Q3, 2024 Results on Feb 29, 2024Elekta AB (publ) announced that they will report Q3, 2024 results on Feb 29, 2024
공시 • May 25+ 1 more updateElekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025Elekta AB (publ) provided earnings guidance for the fiscal year from 2022-2023 to 2024-2025. For the period, the company expects net sales CAGR of above 7%.
공시 • May 13Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONEElekta AB (publ) is excited to announced the launch of the first phase of Elekta ONE, its most comprehensive and advanced software portfolio for oncology departments and clinics, including radiation therapy planning, comprehensive treatment management, and delivery. It brings all Elekta software products, solutions and services under one umbrella providing all users with one unified software experience. Previously, many cancer clinics have wrestled with stand-alone, closed systems, each with a different purpose. The result has been an unfavorable user experience and steep learning curve, adding pressure to an already strained resource: the clinical team. Elekta ONE aims to improve efficiency in the clinic by as much as 50%, eventually through smarter workflows, increased automation, and by learning from every patient treated. Its workflow-driven approach and deep integration between applications allows information to flow freely, giving clinicians a seamless user experience.
공시 • Feb 14Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter.Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter on February 13, 2023. The first quarter of Elekta’s fiscal year 2023-2024.
공시 • Nov 24Elekta AB (publ), Annual General Meeting, Aug 24, 2023Elekta AB (publ), Annual General Meeting, Aug 24, 2023.
공시 • Jul 09+ 1 more updateElekta AB (publ) to Report Fiscal Year 2023 Results on May 25, 2023Elekta AB (publ) announced that they will report fiscal year 2023 results on May 25, 2023